+

WO2008137075A3 - Compositions and methods for the treatment of metabolic disorders and inflammation - Google Patents

Compositions and methods for the treatment of metabolic disorders and inflammation Download PDF

Info

Publication number
WO2008137075A3
WO2008137075A3 PCT/US2008/005686 US2008005686W WO2008137075A3 WO 2008137075 A3 WO2008137075 A3 WO 2008137075A3 US 2008005686 W US2008005686 W US 2008005686W WO 2008137075 A3 WO2008137075 A3 WO 2008137075A3
Authority
WO
WIPO (PCT)
Prior art keywords
stamp2
agents
inflammation
treatment
methods
Prior art date
Application number
PCT/US2008/005686
Other languages
French (fr)
Other versions
WO2008137075A2 (en
Inventor
Gokhan S Hotamisligil
Kathryn E Wellen
Fahri Saatcioglu
Original Assignee
Harvard College
Gokhan S Hotamisligil
Kathryn E Wellen
Fahri Saatcioglu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Gokhan S Hotamisligil, Kathryn E Wellen, Fahri Saatcioglu filed Critical Harvard College
Publication of WO2008137075A2 publication Critical patent/WO2008137075A2/en
Publication of WO2008137075A3 publication Critical patent/WO2008137075A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the discovery of the role of STAMP2 in coordination of responses to both inflammatory and nutritional stimuli. The invention provides for the use of STAMP2 deficient cells and STAMP2 deficient mice for screening for agents to modulate biomarkers associated with inflammation, oxidative stress, and metabolism. The invention also provides for the use of STAMP containing cells, particularly adipose, hepatic, or muscle cells, to identify agents that modulate STAMP2. The invention provide agents identified by the methods of the invention and their use as therapeutic agents for the treatment of metabolic disorders, which frequently include an inflammatory component. The invention also provide kits including STAMP 2 deficient cells.
PCT/US2008/005686 2007-05-02 2008-05-02 Compositions and methods for the treatment of metabolic disorders and inflammation WO2008137075A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92739807P 2007-05-02 2007-05-02
US60/927,398 2007-05-02

Publications (2)

Publication Number Publication Date
WO2008137075A2 WO2008137075A2 (en) 2008-11-13
WO2008137075A3 true WO2008137075A3 (en) 2008-12-31

Family

ID=39791411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005686 WO2008137075A2 (en) 2007-05-02 2008-05-02 Compositions and methods for the treatment of metabolic disorders and inflammation

Country Status (1)

Country Link
WO (1) WO2008137075A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) * 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
KR101809605B1 (en) 2016-05-12 2017-12-15 연세대학교 원주산학협력단 Method for diagnosis of oxidative stress related disease using enzymes having circadian rhythms
CN114586735B (en) * 2020-12-04 2024-02-09 南京大学 Construction and application of Pparg gene site-directed mutagenesis mouse model

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259104A1 (en) * 2002-10-22 2004-12-23 Lamberts Steven Willem Jan Test
WO2005114216A2 (en) * 2005-02-22 2005-12-01 Biomedisinsk Innovasjon As Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2006063213A2 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
US20070015246A1 (en) * 2000-03-24 2007-01-18 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1980148A1 (en) * 2006-01-31 2008-10-15 Takeda Pharmaceutical Company Limited Genetically modified animal and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015246A1 (en) * 2000-03-24 2007-01-18 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20040259104A1 (en) * 2002-10-22 2004-12-23 Lamberts Steven Willem Jan Test
WO2006063213A2 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
WO2005114216A2 (en) * 2005-02-22 2005-12-01 Biomedisinsk Innovasjon As Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1980148A1 (en) * 2006-01-31 2008-10-15 Takeda Pharmaceutical Company Limited Genetically modified animal and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WELLEN KATHRYN E ET AL: "Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis.", CELL 4 MAY 2007, vol. 129, no. 3, 4 May 2007 (2007-05-04), pages 537 - 548, XP002500391, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2008137075A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2010132479A3 (en) Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
WO2009059150A3 (en) Biomarkers for fatty liver disease and methods using the same
AU2019268177A1 (en) Improving resistance to skeletal muscle fatigue
MX2010004113A (en) Composition for regulating lipid metabolism.
MX354212B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors.
WO2012018535A3 (en) Wellness panel
WO2010062863A3 (en) Compositions containing satiogens and methods of use
MY157365A (en) Chemical compounds and uses
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
EP4438129A3 (en) Compositions and methods for modulating apolipoprotein c-iii expression
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
CL2008003407A1 (en) Substituted heterobicyclo aryl- and heteroarylcarbonyl derivative compounds; pharmaceutical composition; preparation procedure; and its use in the treatment and / or prevention of metabolic disorders, mediated by the inhibition of the enzyme hsd-1.
EP1804660A4 (en) System and methods for assessing the neuromuscular pathway prior to nerve testing
IL191293A0 (en) Compositions for regulating metabolic disorders and methods of use thereof
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
EP2281058A4 (en) Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
WO2012067970A3 (en) Transcriptional repression leading to parkinson's disease
WO2007149865A3 (en) Methods and compositions related to inhibition of ceramide synthesis
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
WO2008137075A3 (en) Compositions and methods for the treatment of metabolic disorders and inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754200

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754200

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载